摘要
目的 探讨基于动态对比增强MRI(dynamic contrast enhancement MRI, DCE-MRI)瘤内及瘤周的影像组学模型联合临床、影像学指标预测乳腺癌患者人表皮生长因子受体2(human epidermal growth factor receptor 2, HER-2)表达状态的价值。材料与方法 回顾性收集2018年6月至2022年9月经病理证实为乳腺癌的患者病例资料272例,其中HER-2阳性139例,阴性133例,所有病例均在治疗前进行DCE-MRI检查。采取7:3的比例随机分为训练集和验证集。在训练集中使用皮尔森相关系数、递归特征消除法、逻辑回归对瘤内及瘤周影像组学数据进行降维及模型构建;利用多因素logistic回归筛选临床及影像学资料中的独立危险因素,以此构建临床模型;最终以瘤内、瘤周及临床特征构建联合模型。采用受试者工作特征曲线下面积(area under the curve, AUC)评价模型的效能,应用决策曲线分析(decision curve analysis, DCA)评估模型的临床价值。结果 临床模型、瘤内模型、瘤周模型、瘤内+瘤周模型及联合模型在训练集的AUC分别为0.736、0.784、0.806、0.831、0.854,准确度分别为69.5%、70.5%、75.8%、73.7%、76.8%,敏感度分别为87.6%、53.6%、71.1%、62.9%、72.2%,特异度分别为50.5%、88.2%、80.6%、84.9%、81.7%;在验证集中的AUC分别为0.731、0.724、0.713、0.780、0.799,准确度分别为73.2%、70.7%、68.3%、73.1%、78.0%,敏感度分别为76.2%、61.9%、88.1%、76.2%、78.6%,特异度分别为70.0%、80.0%、47.5%、70.0%、77.5%。经DeLong检验,训练集中联合模型与临床模型、瘤内模型、瘤周模型之间差异有统计学意义(Z=3.660、2.791、2.201,P=0.0003、0.005、0.028),联合模型与瘤内+瘤周模型之间差异无统计学意义(Z=1.583,P=0.114)。结果表明在训练集和验证集中联合模型对预测HER-2的状态优于临床模型、瘤内模型、瘤周模型及瘤内+瘤周模型。DCA显示在训练集中风险阈值在13%~60%时联合模型较临床模型、瘤�
Objective:To investigate the value of dynamic contrast enhancement MRI(DCE-MRI)based intratumoral and peritumoral radiomics models in combination with clinical and imaging indicators to predict the expression status of human epidermal growth factor receptor 2(HER-2)in breast cancer patients.Materials and Methods:A total of 272 patients'information with pathologically confirmed breast cancer from June 2018 to September 2022 were retrospectively collected,including 139 patients with positive HER-2 and 133 patients with negative HER-2.All cases underwent DCE-MRI examination before treatment.All 272 patients were divided into training set and validation set with a ratio of 7:3 by complete randomization method.In the training set Pearson correlation coefficients,recursive feature elimination and logistic regression were used to perform dimensionality reduction and model construction of intratumoral and peritumoral radiomics data.Multivariate logistic regression was used to screen the independent risk factors in clinical and imaging data,so as to construct the clinical model.Finally,the combined model was constructed by using intratumoral,peritumoral and clinical features.Area under the curve(AUC)was used to evaluate the efficacy of the model,and decision curve analysis(DCA)was used to evaluate the clinical value of the model.Results:The AUC of clinical model,intratumoral model,peritumoral model,intratumoral+peritumoral model and combined model in the training set were 0.736,0.784,0.806,0.831,0.854,and the accuracy was 69.5%,70.5%,75.8%,73.7%,76.8%,respectively.The sensitivity was 87.6%,53.6%,71.1%,62.9%,72.2%,and the specificity was 50.5%,88.2%,80.6%,84.9%,81.7%,respectively.In the verification set,the AUC was 0.731,0.724,0.713,0.780,0.799,the accuracy was 73.2%,70.7%,68.3%,73.1%,78.0%,and the sensitivity was 76.2%,61.9%,88.1%,76.2%,78.6%,respectively.The specificity was 70.0%,80.0%,47.5%,70.0%and 77.5%,respectively.By DeLong's test,in the training set there were statistically significant differences between combined
作者
张成孟
丁治民
陈鹏
刘奇峰
任超
ZHANG Chengmeng;DING Zhimin;CHEN Peng;LIU Qifeng;REN Chao(Department of Radiology,Yijishan Hospital of Wannan Medical College,Wuhu 241001,China)
出处
《磁共振成像》
CAS
CSCD
北大核心
2023年第4期68-75,共8页
Chinese Journal of Magnetic Resonance Imaging
基金
中国红十字基金会医学赋能-领航菁英科研项目(编号:XM_HR_YXFN_2021_05_24)
安徽省卫生健康科研项目(编号:AHWJ2022b044)。
关键词
影像组学
时间-信号强度曲线
人类表皮生长因子受体2
预测模型
乳腺癌
磁共振成像
radiomics
time-signal intensity curve
human epidermal growth factor receptor 2
predictive model
breast cancer
magnetic resonance imaging
